Join
Live feed
·
PRReleasevia Quantisnow
Veru Inc. logo

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

ByQuantisnow·Wall Street's wire, on your screen.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERU (Veru Inc.) and more on Quantisnow.